Table 1.
Specific regimens for definitive concurrent chemoradiotherapy for unresectable esophageal squamous cell carcinoma: ongoing trials.
| Registration | Phase | Participants | Population | Study Cohort | Control Cohort | Primary Endpoints | Secondary Endpoints |
|---|---|---|---|---|---|---|---|
| NCT04278287 | I/II | 105 | Pathological T3N1M0-1b and T4N0-1M0-1b ESCC(M1b limited to clavicular or celiac lymph node metastasis) | Radiotherapy (59.92 Gy/28F) + Chemotherapy (Albumin-Bound Paclitaxel + Cisplatin) | LCR | AEs, ORR, DFS, PFS, OS | |
|
NCT04115618 2017-ESCCSIB |
II | 65 | Stage I-IVA ESCC (AJCC 6th,2009) | Chemotherapy (Docetaxel + Cisplatin) + Radiotherapy(63 Gy/28F) | AEs | PFS, OS | |
|
NCT03790553 ESO-Shanghai 12 |
III | 646 | T1N1-3M0, T2-4NxM0, TxNxM1 ESCC (supraclavicular lymph node metastasis only)(AJCC 8th) | Chemotherapy (NP) + Radiotherapy (50.4Gy/28F, involved field irradiation) | Chemotherapy (NP) + Radiotherapy (61.2Gy/34F, involved field irradiation) | OS | LCR, PFS, QoL |
T, Tumor; N, regional lymph node; M, Metastasis; ESCC, esophageal squamous cell carcinoma; AJCC, American Joint Committee on Cancer; NR, not reported; F, fraction; LCR, Local control rate; AEs, adverse events; ORR, objective response rate; DFS, disease-free survival; PFS, progression-free survival; OS, overall survival; QoL, quality of life.